Therapy-related acute myeloid leukemia and myelodysplastic syndrome after hematopoietic cell transplantation for lymphoma

被引：17

作者：

Yamasaki, S. ^{[1
,2
]}

Suzuki, R. ^{[3
]}

Hatano, K. ^{[4
]}

Fukushima, K. ^{[5
]}

Iida, H. ^{[6
]}

Morishima, S. ^{[7
]}

Suehiro, Y. ^{[8
]}

Fukuda, T. ^{[9
]}

Uchida, N. ^{[10
]}

Uchiyama, H. ^{[11
]}

Ikeda, H. ^{[12
]}

Yokota, A. ^{[13
]}

Tsukasaki, K. ^{[14
]}

Yamaguchi, H. ^{[15
]}

Kuroda, J. ^{[16
]}

Nakamae, H. ^{[17
]}

Adachi, Y. ^{[18
]}

Matsuoka, K-I ^{[19
]}

Nakamura, Y. ^{[20
]}

Atsuta, Y. ^{[21
,22
]}

Suzumiya, J. ^{[3
]}

机构：

[1] Natl Hosp Org, Kyushu Med Ctr, Dept Hematol, Fukuoka, Japan

[2] Natl Hosp Org, Kyushu Med Ctr, Clin Res Inst, Fukuoka, Japan

[3] Shimane Univ Hosp, Dept Oncol & Haematol, Izumo, Shimane, Japan

[4] Jichi Med Univ, Div Hematol & Cell Therapy, Shimotsuke, Japan

[5] Rinku Gen Med Ctr, Div Hematol, Izumisano, Japan

[6] Natl Hosp Org, Nagoya Med Ctr, Div Cell Therapy, Nagoya, Aichi, Japan

[7] Fujita Hlth Univ, Dept Hematol & Oncol, Sch Med, Toyoake, Aichi, Japan

[8] Natl Hosp Org, Kyushu Canc Ctr, Dept Hematol, Fukuoka, Japan

[9] Natl Canc Ctr, Div Hematopoiet Stem Cell Transplantat, Tokyo, Japan

[10] Toranomon Gen Hosp, Federat Natl Publ Serv Personnel Mutual Aid Assoc, Dept Hematol, Tokyo, Japan

[11] Japanese Red Cross Kyoto Daiichi Hosp, Dept Hematol, Kyoto, Japan

[12] Sapporo Med Univ Hosp, Dept Gastroenterol Rheumatol & Clin Immunol, Sapporo, Hokkaido, Japan

[13] Chiba Aoba Municipal Hosp, Dept Hematol, Chiba, Japan

[14] Natl Canc Ctr Hosp East, Hematol Div, Kashiwa, Chiba, Japan

[15] Nippon Med Sch, Dept Hematol, Tokyo, Japan

[16] Kyoto Prefectural Univ Med, Dept Med, Div Hematol & Oncol, Kyoto, Japan

[17] Osaka City Univ Hosp, Dept Hematol, Osaka, Japan

[18] Japan Community Hlth Care Org, Kobe Cent Hosp, Dept Internal Med, Kobe, Hyogo, Japan

[19] Okayama Univ Hosp, Div Hematol & Oncol, Okayama, Japan

[20] Yamaguchi Univ, Dept Internal Med 3, Sch Med, Ube, Yamaguchi, Japan

[21] Nagoya Univ, Dept Healthcare Adm, Grad Sch Med, Nagoya, Aichi, Japan

[22] Japanese Data Ctr Hematopoiet Cell Transplantat, Nagoya, Aichi, Japan

来源：

BONE MARROW TRANSPLANTATION | 2017年 / 52卷 / 07期

关键词：

STAGE HODGKINS LYMPHOMA; SECONDARY LEUKEMIA; RISK; DISEASE; TRIAL;

D O I：

10.1038/bmt.2017.52

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

Therapy-related acute myeloid leukemia and myelodysplastic syndrome (t-AML/MDS) represent severe late effects in patients receiving hematopoietic cell transplantation (HCT) for lymphoma. The choice between high-dose therapy with autologous HCT and allogeneic HCT with reduced-intensity conditioning remains controversial in patients with relapsed lymphoma. We retrospectively analyzed incidence and risk factors for the development of t-AML/MDS in lymphoma patients treated with autologous or allogeneic HCT. A total of 13 810 lymphoma patients who received autologous (n = 9963) or allogeneic (n = 3847) HCT between 1985 and 2012 were considered. At a median overall survival (OS) of 52 and 46 months in autologous and allogeneic HCT groups, respectively, lymphoma patients receiving autologous HCT (1.38% at 3 years after autologous HCT) had a significant risk for developing t-AML/ MDS compared to allogeneic HCT (0.37% at 3 years after allogeneic HCT, P < 0.001). Significant risk factors for the development of t-AML/MDS after autologous and allogeneic HCT were high-stage risk at HCT (P = 0.04) or secondary malignancies (Po0.001) and receiving cord blood stem cell (P = 0.03) or involved field radiotherapy (P = 0.002), respectively. Strategies that carefully select lymphoma patients for autologous HCT, by excluding lymphoma patients with high-stage risk at HCT, may allow the identification of individual lymphoma patients at particular high risk for t-AML/MDS.

引用

页码：969 / 976

页数：8

共 23 条

[1] Outcomes of patients with therapy-related AML/myelodysplastic syndrome (t-AML/MDS) following hematopoietic cell transplantation [J].

Alam, N. ;

Atenafu, E. G. ;

Kuruvilla, J. ;

Uhm, J. ;

Lipton, J. H. ;

Messner, H. A. ;

Kim, D. H. ;

Seftel, M. ;

Gupta, V. .

BONE MARROW TRANSPLANTATION, 2015, 50 (09) :1180-1186

[2]

André M, 1998, BLOOD, V92, P1933

[3] A disease risk index for patients undergoing allogeneic stem cell transplantation [J].

Armand, Philippe ;

Gibson, Christopher J. ;

Cutler, Corey ;

Ho, Vincent T. ;

Koreth, John ;

Alyea, Edwin P. ;

Ritz, Jerome ;

Sorror, Mohamed L. ;

Lee, Stephanie J. ;

Deeg, H. Joachim ;

Storer, Barry E. ;

Appelbaum, Frederick R. ;

Antin, Joseph H. ;

Soiffer, Robert J. ;

Kim, Haesook T. .

BLOOD, 2012, 120 (04) :905-913

[4] Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP system [J].

Atsuta, Yoshiko ;

Suzuki, Ritsuro ;

Yoshimi, Ayami ;

Gondo, Hisashi ;

Tanaka, Junji ;

Hiraoka, Akira ;

Kato, Koji ;

Tabuchi, Ken ;

Tsuchida, Masahiro ;

Morishima, Yasuo ;

Mitamura, Makoto ;

Kawa, Keisei ;

Kato, Shunichi ;

Nagamura, Tokiko ;

Takanashi, Minoko ;

Kodera, Yoshihisa .

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2007, 86 (03) :269-274

[5] Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data) [J].

Atsuta, Yoshiko .

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2016, 103 (01) :3-10

[6] Therapy-related myelodysplasia and/or acute myeloid leukaemia after autologous haematopoietic progenitor cell transplantation in a prospective single centre cohort of 221 patients [J].

Beauchamp-Nicoud, A ;

Feneux, D ;

Bayle, C ;

Bernheim, A ;

Léonard, C ;

Koscielny, S ;

Tchernia, G ;

Bourhis, JH .

BRITISH JOURNAL OF HAEMATOLOGY, 2003, 122 (01) :109-117

[7] 11q23 balanced chromosome aberrations in treatment- related myelodysplastic syndromes and acute leukemia:: Report from an international workshop [J].

Bloomfield, CD ;

Archer, KJ ;

Mrózek, K ;

Lillington, DM ;

Kaneko, Y ;

Head, DR ;

Dal Cin, P ;

Raimondi, SC .

GENES CHROMOSOMES & CANCER, 2002, 33 (04) :362-378

[8] IMPORTANCE OF BONE-MARROW CYTOGENETIC EVALUATION BEFORE AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR HODGKINS-DISEASE [J].

CHAO, NJ ;

NADEMANEE, AP ;

LONG, GD ;

SCHMIDT, GM ;

DONLON, TA ;

PARKER, P ;

SLOVAK, ML ;

NAGASAWA, LS ;

BLUME, KG ;

FORMAN, SJ .

JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (09) :1575-1579

[9] Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group [J].

Eichenauer, Dennis A. ;

Thielen, Indra ;

Haverkamp, Heinz ;

Franklin, Jeremy ;

Behringer, Karolin ;

Halbsguth, Teresa ;

Klimm, Beate ;

Diehl, Volker ;

Sasse, Stephanie ;

Rothe, Achim ;

Fuchs, Michael ;

Boell, Boris ;

von Tresckow, Bastian ;

Borchmann, Peter ;

Engert, Andreas .

BLOOD, 2014, 123 (11) :1658-1664

[10] Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial [J].

Engert, Andreas ;

Haverkamp, Heinz ;

Kobe, Carsten ;

Markova, Jana ;

Renner, Christoph ;

Ho, Antony ;

Zijlstra, Josee ;

Kral, Zdenek ;

Fuchs, Michael ;

Hallek, Michael ;

Kanz, Lothar ;

Doehner, Hartmut ;

Doerken, Bernd ;

Engel, Nicole ;

Topp, Max ;

Klutmann, Susanne ;

Amthauer, Holger ;

Bockisch, Andreas ;

Kluge, Regine ;

Kratochwil, Clemens ;

Schober, Otmar ;

Greil, Richard ;

Andreesen, Reinhard ;

Kneba, Michael ;

Pfreundschuh, Michael ;

Stein, Harald ;

Eich, Hans Theodor ;

Mueller, Rolf-Peter ;

Dietlein, Markus ;

Borchmann, Peter ;

Diehl, Volker .

LANCET, 2012, 379 (9828) :1791-1799

← 1 2 3 →